Neues einmal wöchentliches Basisinsulin bei Langzeitblutzuckerkontrolle nicht unterlegen

1 https://adisinsight.springer.com/drugs/800048169

2 Bergenstal RM et al. Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial. Lancet 2024; https://doi.org/10.1016/S0140-6736(24)01804-X

3 Wysham C et al. Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment. N Engl J Med 2024; https://doi.org/10.1056/NEJMoa2403953

4 Brodsky I. A New Once-Weekly Insulin - Its Effectiveness and Safety. N Engl J Med 2024; https://doi.org/10.1056/nejme2410551

5 Rosenstock J et al. The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa. Endocr Rev 2024;45(3):379–413

6 Shah AS, Wolf RM. Weekly insulin: a paradigm shift in type 1 diabetes therapy. Lancet 2023;402(10413):1598–1599

7 https://adisinsight.springer.com/drugs/800037853